GALLIUM研究中CHOP方案对比苯达莫司汀方案对惰性淋巴瘤患者骨密度的影响
该研究为GALLIUM事后分析,纳入173例≥60岁完成诱导治疗的滤泡性淋巴瘤患者,比较CHOP与苯达莫司汀方案对骨密度的影响。从基线至诱导治疗完成时,CHOP组腰椎HU平均下降27.8,苯达莫司汀组下降17.3,校正差异为10.4(95%CI:3.2-17.6)。CHOP组椎体骨折5/59例,苯达莫司汀组2/114例。CHOP与骨密度更大幅度下降及更频繁骨折相关,结果提示应考虑预防骨密度丢失。
要点
- CHOP组从基线至诱导治疗完成时腰椎HU平均下降27.8,苯达莫司汀组下降17.3。
- 校正差异为10.4(95%CI:3.2-17.6),CHOP与骨密度更大幅度下降相关。
- CHOP组椎体骨折5/59例,苯达莫司汀组2/114例,CHOP与更频繁骨折相关。
核心结论
- CHOP与骨密度更大幅度下降及更频繁骨折相关,结果提示应考虑预防骨密度丢失。
研究设计与样本
- GALLIUM研究的事后分析,纳入173例≥60岁完成诱导治疗且达完全缓解的滤泡性淋巴瘤患者,其中59例(34%)接受CHOP,114例(66%)接受苯达莫司汀,比较两组骨密度变化。
主要发现
- 从基线至诱导治疗完成时,CHOP组腰椎L1的HU平均下降27.8,苯达莫司汀组平均下降17.3,校正差异为10.4(95%CI:3.2-17.6)。
- 椎体骨折在CHOP组记录为5/59例,在苯达莫司汀组为2/114例。
- 基线时两组HU无差异。
关键数值与推荐
- 骨密度通过年度CT测量腰椎L1的Hounsfield单位(HU)评估,并记录椎体压缩性骨折。
临床怎么用
- 原文结论指出结果提示应考虑预防骨密度丢失。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Standard CHOP treatment includes a high cumulative dose of prednisone, and studies have shown increased fracture risk following CHOP. It is unclear whether reductions in bone mineral density (BMD) are caused by glucocorticoids or by the combination with chemotherapy. Our objective was to determine the effect of obinutuzumab (G)/rituximab (R)-bendamustine versus G/R-CHOP on BMD in follicular lymphoma patients. Patients in this GALLIUM post hoc study were ≥60 years old and in complete remission at induction treatment completion (ITC), following treatment with G or R in combination with bendamustine or CHOP. To assess BMD, Hounsfield units (HU) were measured in lumbar vertebra L1 on annual computed tomography. Furthermore, vertebral compression fractures were recorded. Of 173 patients included, 59 (34%) received CHOP and 114 (66%) received bendamustine. At baseline, there was no difference in HU between groups. The mean HU decrease from baseline to ITC was 27.8 after CHOP and 17.3 after bendamustine, corresponding to a difference of 10.4 (95% CI: 3.2-17.6). Vertebral fractures were recorded in 5/59 patients receiving CHOP and in 2/114 receiving bendamustine. CHOP was associated with a significant greater decrease in BMD and more frequent fractures. These results suggest that prophylaxis against BMD loss should be considered.
引用
- Pedersen MA, Gormsen LC, Jakobsen LH, et al. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. Br J Haematol. 2023. PMID: 37957542. doi:10.1111/bjh.19194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。